On Drugs

On Drugs Your article1 implied that there are scientific reasons why research-ers don't support drug decriminalization. But there's a much better explanation: They want to keep their jobs and their grants. NIDA [National Institute on Drug Abuse] assistant director Hanson wouldn't even support needle exchange--for which the evidence is overwhelming--when the chips were down. Director Volkow claims, despite the evidence, that we don't know yet whether marijuana is toxic to the adolescent brai

Written byMaia Szalavitz
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Your article1 implied that there are scientific reasons why research-ers don't support drug decriminalization. But there's a much better explanation: They want to keep their jobs and their grants.

NIDA [National Institute on Drug Abuse] assistant director Hanson wouldn't even support needle exchange--for which the evidence is overwhelming--when the chips were down. Director Volkow claims, despite the evidence, that we don't know yet whether marijuana is toxic to the adolescent brain.

But, we've run a natural experiment on that question for the last 30 years, with teen-use rates ranging from 50% to 70% around the developed world. If marijuana were really harmful, we should have seen some evidence by now. Despite an exhaustive search (and remember that studies showing no effect are far less likely to get published), there's no evidence for significant, permanent impairment even in the heaviest users. There's no evidence to support the notion that pot leads ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies